Shizuoka, Japan

Kazuki Kato

This inventor holds 3 USPTO granted patents and 5 published patent applications. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazuki Kato. Retrieved from https://idiyas.com/inventor/kazuki-kato-q6li53bn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2020-2026

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Kazuki Kato: Inventor in Biopharmaceutical Research

Introduction

Kazuki Kato is an inventor associated with Shizuoka, Japan, and Chugai Seiyaku Kabushiki Kaisha. His patent work includes research into antibody molecules designed to support blood coagulation.

Latest Patents

Kato’s listed recent patent titles include “Bispecific Antibody Exhibiting Increased Alternative FVIII-Cofactor-Function Activity” and “Multispecific Antigen-Binding Molecules Having Blood Coagulation Factor VIII (FVIII) Cofactor Function-Substituting Activity and Pharmaceutical Formulations Containing Such a Molecule as an Active Ingredient.” These inventions concern antibody-based approaches to FVIII cofactor activity.

Career Highlights

The provided information credits Kato with 3 patents and identifies Chugai Seiyaku Kabushiki Kaisha as the company where he works.

Collaborations

Kato’s listed coworkers include Yuri Teranishi and Hikaru Koga.

Conclusion

Kazuki Kato’s recorded patent portfolio reflects work on multispecific antibodies and blood-coagulation-related applications at Chugai Seiyaku Kabushiki Kaisha.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…